IF 5.4 2区 医学 Q1 IMMUNOLOGY
BioDrugs Pub Date : 2025-03-01 Epub Date: 2025-02-05 DOI:10.1007/s40259-025-00706-4
Virginia Solitano, Maria Manuela Estevinho, Federica Ungaro, Fernando Magro, Silvio Danese, Vipul Jairath
{"title":"TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review.","authors":"Virginia Solitano, Maria Manuela Estevinho, Federica Ungaro, Fernando Magro, Silvio Danese, Vipul Jairath","doi":"10.1007/s40259-025-00706-4","DOIUrl":null,"url":null,"abstract":"<p><p>Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), remains challenging to manage, with a substantial proportion of patients not responding to conventional therapies or developing complications. The tumor necrosis factor (TNF) superfamily member TL1A has emerged as an important player in the pathogenesis of IBD, influencing pathways of inflammation and fibrosis. This leading article reviews the role of TL1A in IBD, evaluates the efficacy of anti-TL1A therapies in clinical trials, and discusses future directions for research and treatment. TL1A is implicated in IBD through its interaction with death domain receptor 3 (DR3), promoting T-cell activation and contributing to both inflammatory responses and fibrotic changes. Phase 2 clinical trials of anti-TL1A agents have demonstrated promising results, showing improvements in endoscopic and histologic outcomes for both UC and CD. Phase 2 and 3 clinical trials are ongoing, which are expected to provide further clarity on the efficacy and safety of TL1A-targeting agents in treating IBD.</p>","PeriodicalId":9022,"journal":{"name":"BioDrugs","volume":" ","pages":"171-183"},"PeriodicalIF":5.4000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BioDrugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40259-025-00706-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/2/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

炎症性肠病(IBD)包括克罗恩病(CD)和溃疡性结肠炎(UC),其治疗仍然具有挑战性,相当一部分患者对传统疗法无效或出现并发症。肿瘤坏死因子(TNF)超家族成员TL1A已成为IBD发病机制中的一个重要角色,它影响着炎症和纤维化的途径。这篇重要文章回顾了TL1A在IBD中的作用,评估了临床试验中抗TL1A疗法的疗效,并讨论了未来的研究和治疗方向。TL1A与死亡结构域受体3(DR3)相互作用,促进T细胞活化并导致炎症反应和纤维化改变,从而与IBD有关。抗TL1A药物的二期临床试验结果很有希望,显示UC和CD的内镜和组织学结果均有所改善。2 期和 3 期临床试验正在进行中,有望进一步明确 TL1A 靶向药物治疗 IBD 的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review.

Inflammatory bowel disease (IBD), encompassing Crohn's disease (CD) and ulcerative colitis (UC), remains challenging to manage, with a substantial proportion of patients not responding to conventional therapies or developing complications. The tumor necrosis factor (TNF) superfamily member TL1A has emerged as an important player in the pathogenesis of IBD, influencing pathways of inflammation and fibrosis. This leading article reviews the role of TL1A in IBD, evaluates the efficacy of anti-TL1A therapies in clinical trials, and discusses future directions for research and treatment. TL1A is implicated in IBD through its interaction with death domain receptor 3 (DR3), promoting T-cell activation and contributing to both inflammatory responses and fibrotic changes. Phase 2 clinical trials of anti-TL1A agents have demonstrated promising results, showing improvements in endoscopic and histologic outcomes for both UC and CD. Phase 2 and 3 clinical trials are ongoing, which are expected to provide further clarity on the efficacy and safety of TL1A-targeting agents in treating IBD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
BioDrugs
BioDrugs 医学-免疫学
CiteScore
12.60
自引率
2.90%
发文量
50
审稿时长
>12 weeks
期刊介绍: An essential resource for R&D professionals and clinicians with an interest in biologic therapies. BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease. BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信